EULAR 2025: Tonix highlights transmucosal Cyclobenzaprine’s impact on sleep and pain in Fibromyalgia
Tonix Pharmaceuticals Holding Corp. announced a poster presentation at the Annual European Congress of Rheumatology (EULAR) 2025, being held June 11-14, 2025, in Barcelona, Spain. Details on the presentation can be found below.
A copy of the Company’s poster presentation will be available under the Scientific Presentations tab of the Tonix website at www.tonixpharma.com following the conference.
| Poster Presentation Details | |
| Presenter: | Iredell Iglehart, M.D. |
| Title: | Advancing Fibromyalgia Treatment: Transmucosal Sublingual Cyclobenzaprine (TNX-102 SL1) Targets Non-restorative Sleep and Provides Sustained Pain Reduction |
| Poster No.: | POS02016 |
| Session: | Basic and Clinical Poster Tours: Pain in Rheumatic Musculoskeletal Diseases |
| Date/Time: | Friday, June, 13, 2025, 12:48 p.m. CEST |
